{'fraction_non_alphanumeric': 0.04674457429048414, 'fraction_numerical': 0.005008347245409015, 'mean_word_length': 5.593406593406593, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results

Treatment of hepatitis C virus (HCV) genotype 4 patient with fixed dose combination of ombitasvir‐paritaprevir‐ritonavir plus ribavirin (OBV/rPTV/RBV) has been proven efficacy and safety in many clinical trials. The current study reports the efficacy and safety of OBV/rPTV/RBV (for treatment‐naïve), and OBV/rPTV/RBV/sofosbuvir (SOF) (for treatment‐experienced), in chronic HCV genotype 4 patients in real life settings.